Leap Therapeutics

picture of an individual leaping between boulders

Biotech

BeiGene lets option on Leap’s immuno-oncology candidate lapse

Three years with a front-row seat for the development of DKN-01 failed to persuade BeiGene to pull the trigger on a deal for the oncology candidate.

Nick Paul Taylor Mar 17, 2023 8:50am

picture of an individual leaping between boulders

3 biotechs consolidate as M&A fails to materialize at JPM

Jan 17, 2023 11:14am